Literature DB >> 33165845

Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies.

Michaela Kotrova1, Nikos Darzentas1, Christiane Pott1, Monika Brüggemann2.   

Abstract

Next-generation sequencing (NGS) of immunoglobulin (IG) and T cell receptor (TR) rearrangements represents a modern alternative to classical RQ-PCR-based minimal residual disease (MRD) detection. The same primer sets and conditions can be used for all patients, which is undoubtedly one of the most important benefits of NGS, not only reducing the labor required to perform the analysis but also enabling the assay to comply with the upcoming EU IVD regulation. So far, only one standardized academic protocol for this task has been published, developed, and validated within the EuroClonality-NGS working group. In this chapter we describe the materials and methods for amplicon library preparation for sequencing on Illumina MiSeq, and the bioinformatic pipeline for this protocol.

Entities:  

Keywords:  Amplicon sequencing; Bioinformatics; Immunoglobulin; Library preparation; Minimal residual disease; Next-generation sequencing; Rearrangement; T cell receptor

Mesh:

Substances:

Year:  2021        PMID: 33165845     DOI: 10.1007/978-1-0716-0810-4_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

1.  Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Authors:  Eva Giné; Fátima de la Cruz; Ana Jiménez Ubieto; Javier López Jimenez; Alejandro Martín García-Sancho; M José Terol; Eva González Barca; María Casanova; Adolfo de la Fuente; Ana Marín-Niebla; Ana Muntañola; Tomás José González-López; Marta Aymerich; Xavier Setoain; Montserrat Cortés-Romera; Amanda Rotger; Sonia Rodríguez; Alejandro Medina Herrera; Ramón García Sanz; Ferran Nadeu; Silvia Beà; Elías Campo; Armando López-Guillermo
Journal:  J Clin Oncol       Date:  2022-01-14       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.